Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma DiveFoundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Lilly bags FDA okay for Wegovy pill rival orforglipronNext: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
